EPIDEMIOLOGY AND CLINICO-DEMOGRAPHIC CHARACTERISTICS OF DIFFUSE LARGE B-CELL LYMPHOMA IN THE NOVOSIBIRSK CITY

Background. The annual reporting forms for malignant neoplasms do not provide for the division of lymphomas into variants. In international publications and statistical reference books of the Russian Federation, variants of non-Hodgkin’s lymphomas (NHL) are also not separated. For these reasons, a detailed assessment of the epidemiology of NHL in Russia is difficult, and data for individual variants of the disease are not provided.

Purpose: to present the clinical and epidemiological characteristics of Diffuse Large B-cell Lymphoma (DL BCL ) in Novosibirsk according to the data of the City Hematology Center (CHC).

Material and Methods. A retrospective analysis of primary medical documentation (case histories,  outpatient charts, and immunohistochemical study reports) of 271 patients with DL BCL was performed in the period from January 1, 2013 to December 31, 2018.

Results. The calculated registered primary morbidity and mortality from DL BCL in Novosibirsk for the analyzed years fluctuated slightly. The average incidence and mortality rates were 2.85 and 1.98 per 100,000 population, respectively. When analyzing the dynamics of the prevalence of DL BCL in Novosibirsk, a positive trend of annual increase in the indicator was revealed: 1.87 times over the past 6 years. In men, the tumor developed 2.6 years earlier than in women. In General, the risk of getting DL BCL after 50 years was 3 times higher than at the age of 30 years. Among patients diagnosed with primary lymphoma who underwent treatment at the Hematology department of CHC, half of the patients had DL BCL .Evaluation of the clinical characteristics showed a pronounced severity of the analyzed cohort.

Conclusion. The updated quantitative and qualitative indicators of clinical and epidemiological characteristics of DL BCL in Novosibirsk for 2013–18 were obtained. These indicators can be used for further monitoring, development and implementation of measures for the prevention, diagnosis and treatment of this form of hemoblastosis. 

1. Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2018 (morbidity and mortality). Moscow, 2019; 250 p. (in Russian).

2. WHO. CI5: cancer incidence in five continents [Internet]. URL: http://ci5.iarc.fr/Default.aspx (cited 07.04.2020).

3. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours. Revised 4th Edition. 2017; 2: 589.

4. International Statistical Classification of Diseases and Related Health Problems 10th Revision. [Internet]. URL: https://mkb-10.com. (cited: 07.04.2020). (in Russian).

5. Kovinev I.В., Pospelova T.I., Ageeva T.A., Loseva M.I., Voropaeva E.N., Djachkova N.Yu. Non-hodgkin’s lymphoma, immunomorphology, WHO-classification of the lymphomas, epidemiology of the lymphomas. The Bulletin of Siberian Branch of Russian Academy of Medical Sciences. 2006; 26(4): 175–81. (in Russian).

6. Zubkova E.V., Dvornichenko V.V. Epidemiology of non-hodgkin’s lymphomas in Irkutsk region. Bulletin of the East Siberian Scientific Center SB RAMS. 2012; 3(85): 93–96. (in Russian).

7. Zverev A.M., Ruzhnikova A.A., Levit M.L., Burdaeva O.N. Epidemiology of Hodgkin’s lymphoma and non-Hodgkin’s lymphomas in the Arkhangelsk region from 2000 to 2009. Hematology and transfusiology. 2014; 59 (1): 95. (in Russian).

8. Botvinkin A.D., Batoroev Y.K., Morand Patrice, Semenova T.V., Bayanova T.A., Zubrinsky K.G., Lapshina G.V., Dvornichenko V.V., Plotnikova Y.K. Epidemiology of malignant limphomas in region with high prevalence of hiv-infection. HIV Infection and Immunosuppressive Disorders. 2015; 7(3): 118–125. (in Russian).

9. Voropaeva E.N., Pospelova T.I., Voevoda M.I. TP53 gene in diffuse large B-cell lymphoma. Novosibirsk, 2018. 164 p. (in Russian).

10. Voropaeva E.N., Voevoda M.I., Maksimov V.N., Pospelova T.I. Linkage disequilibrium and haplotypes of the rs1042522, rs1625895, and rs1787862 markers of tp53 in patients with diffuse large b-cell lymphoma. Molecular Biology. 2014; 48(5): 664–670.

11. Voropaeva E.N., Pospelova T., Voevoda M.I. Association of DNA repair gene xrcc1 polymorphism arg399gln with high-grade nonhodgkin’s lymphoma risk. Russian journal of hematology and transfusiology. 2013; 58(1): 10–14. (in Russian).

12. Berezina O.V., Weiner A.S., Voropaeva E.N. The effect of single nucleotide substitutions in the folate cycle genes on the risk of developing aggressive non-Hodgkin’s lymphomas. Siberian Medical Review. 2011; 3 (69): 2226. (in Russian).

13. Voropaeva E.N., Voevoda M.I., Pospelova T.I., Maksimov V.N. Intronic polymorphisms of аntionkogene TP53 in patients with indolent variants of non-Hodgkin’s lymphomas. Advances in Gerontology. 2013; 26(2): 258–262. (in Russian).

14. Average annual population [Internet]. URL: http://novosibstat.old.gks.ru/wps/wcm/connect/rosstat_ts/novosibstat/ru/statistics/population/. (cited: 20.11.2019). (in Russian).

15. Pospelova T.I., Shpagina L.A., Nechunaeva I.N., Maslova L.M., Kovynev I.B., Klimchuk T.V., Khalzov K.V., Marinkin I.O., Lihanov A.V., Ivaninskiy O.I. The operation model of hematological care system in Novosibirsk Region. Siberian Medical Journal. 2017; 32(2): 70–75. (in Russian).

16. Kozyayeva E.V., Loseva M.I., Dalmatov G.A. Morbidity and mortality from hemoblastosis taking into account environmental and technogenic factors. Journal of Experimental and Clinical Medicine. 2003; 1: 29–36. (in Russian).

17. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non- Hodgkin’s lymphoma. N Engl J Med. 1993 Sep 30; 329(14): 987–94. doi: 10.1056/NEJM199309303291402.

18. Jaffe E.S. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009: 523–31. doi: 10.1182/asheducation-2009.1.523.

19. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., Müller-Hermelink H.K., Campo E., Braziel R.M., Jaffe E.S., Pan Z., Farinha P., Smith L.M., Falini B., Banham A.H., Rosenwald A., Staudt L.M., Connors J.M., Armitage J.O., Chan W.C. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1): 275–82. doi: 10.1182/blood-2003-05-1545.

20. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec; 5(6): 649–55.

21. Bray F., Colombet M., Mery L., Piñeros M., Znaor A., Zanetti R., Ferlay J. Cancer Incidence in Five Continents, Vol. XI (Internet). Lyon: International Agency for Research on Cancer. URL: https://ci5.iarc.fr (cited: 20.11.2019).

22. Poddubnaya I. V., Savchenko V.G. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Moscow, 2013. 104 p. (in Russian).